Blocking ELISA kit and method for detecting Lawsonia intracellularis antibody

By developing a blocking ELISA kit for Intracellular Lawsonia, the LI-OmpA recombinant antigen peptide and monoclonal antibody 5F2 were used to solve the cumbersome sample processing and detection delay in the diagnosis method of Intracellular Lawsonia in the prior art. , achieving high accuracy and early detection of infection.

CN119044482AActive Publication Date: 2024-11-29HUAZHONG AGRI UNIV

Patent Information

Application Number
CN202411081438.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-08
Publication Date
2024-11-29
Estimated Expiration
2044-08-08

AI Technical Summary

Technical Problem

Existing intracellular Lawsonian diagnostic methods such as PCR and serological testing have problems such as cumbersome sample processing, high false negative rate and delayed detection, especially in the detection of large-scale samples and early detection of infection.

Method used

A blocking ELISA kit for detecting intracellular Lawsoni antibodies was developed. Using LI-OmpA recombinant antigen peptide and monoclonal antibody 5F2 against it, the antibodies in serum were detected through ELISA technology, which increased the sensitivity of the detection. Sex and specificity.

Benefits of technology

This kit has good conservative, thermal stability and immunogenicity, can accurately detect antibodies in serum, improve the accuracy and repeatability of the detection, is suitable for early infection detection, and has good specificity and sensitivity. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119044482A_ABST
    Figure CN119044482A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of diagnosis of pathogenic bacteria of livestock, and particularly relates to a blocking ELISA (enzyme-linked immunosorbent assay) kit and method for detecting an intracellular Lawsonia antibody. The kit comprises an LI-OmpA recombinant antigen peptide coated ELISA plate, an enzyme-labeled antibody, a positive control, a negative control, a sample diluent, a 20-fold concentrated washing solution, a substrate developing solution and a stop solution. According to the method, an LI-OmpA recombinant antigen peptide is used as a coating antigen, an enzyme-labeled LI-OmpA recombinant antigen peptide monoclonal antibody 5F2 is used as an enzyme-labeled antibody, and the lawsonia intracellularis antibody blocking ELISA method is established. The detection method of the lawsonia intracellularis antibody blocking ELISA kit has the characteristics of high sensitivity and specificity, good repeatability and the like, and is suitable for detection of high-flux animal serum samples.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of diagnosis of pathogenic bacteria of livestock, and particularly relates to a blocking ELISA kit and method for detecting antibodies of Lawsonia intracellularis. Background Art

[0002] Lawsonia intracellularis (LI) mainly causes porcine proliferative enteropathy (PPE), whose typical symptoms are proliferative hemorrhagic enteropathy (PHE) and porcine intestinal adenoma (PIA).

[0003] At present, the methods used to diagnose Lawsonia intracellularis infection at home and abroad are mainly serology and various PCR methods for testing fecal samples. PCR is the most commonly used means of pathogen detection in laboratories and clinics. PCR is only suitable for the detection of fecal samples of infected animals during the bacterial excretion period. The steps for extracting the genome from feces are relatively cumbersome and not suitable for testing a large number of samples. It is also prone to false negatives due to the influence of medication. Serological diagnosis mainly relies on enzyme-linked immunosorbent assay (ELISA) and indirect immunofluorescence assay (IFA). These two methods not only have high sensitivity and specificity, but also the specific antibodies against Lawsonia intracellularis can exist in the body for a longer time. The disadvantage is that the antibodies can only be detected at least two weeks after infection.

[0004] Since there is no commercial blocking ELISA detection kit in serological diagnosis in China, it is necessary to provide a blocking ELISA kit to fill the gap in this field. Summary of the invention

[0005] The purpose of the present invention is to provide a blocking ELISA kit capable of conveniently and rapidly detecting antibodies to Lawsonia intracellularis, the detection sensitivity and specificity of the kit are good, and the detection result is accurate.

[0006] Specifically, the technical solution of the present invention is as follows:

[0007] A blocking ELISA kit for detecting antibodies to intracellular Lawsonia ovale, comprising an ELISA plate coated with a LI-OmpA recombinant antigen peptide, targeting the amino acid sequence of the LI-OmpA recombinant antigen peptide as shown in the sequence table SEQ ID NO: 1, including a LI-OmpA recombinant antigen peptide monoclonal antibody 5F2 labeled with horseradish peroxidase, i.e., an enzyme-labeled antibody, targeting the LI-OmpA recombinant antigen peptide monoclonal antibody 5F2 (monoclonal antibody 5F2 is produced by hybridoma cell line 5F2, and the hybridoma cell line 5F2 was submitted by the applicant to the China Center for Type Culture Collection, Wuhan University, China, on September 15, 2023 for preservation; the preservation number is CCTCC NO: C2023263).

[0008] As an optional or preferred technical solution, in the above-mentioned kit, the nucleotide sequence of the LI-OmpA recombinant antigen peptide is as shown in SEQ ID NO:2.

[0009] As an optional or preferred technical solution, in the above kit, the LI-OmpA recombinant antigen peptide can be prepared by the following method steps:

[0010] 1) Obtain the nucleic acid and amino acid sequences of ompA of strain LI.N343 from the NCBI website and use the live vaccine of porcine ileitis as

[0011] The DNA extracted from the bacterial solution was used as a template, and the nucleotides shown in SEQ ID NO: 3-4 in the sequence table were used as primers to clone the ompA sequence without a signal peptide and a transmembrane region.

[0012] 2) The target gene and the vector pET 30a(+) were digested with double enzymes and then connected to construct the pet 30a-ompA prokaryotic expression vector, which was transformed into Escherichia coli BL21, cultured, and positive clones were identified.

[0013] 3) After correct identification, the recombinant plasmid bacteria were inoculated into LB medium containing kanamycin and cultured at 37°C with shaking until the logarithmic growth phase.

[0014] 4) Add IPTG with a final concentration of 0.8 mmol / L, induce at 25°C for 16 h, and obtain the expression of LI-OmpA recombinant antigen peptide.

[0015] 5) After the bacteria are crushed and centrifuged, the supernatant is purified by His tag affinity chromatography. The antigen liquid obtained after dialysis and concentration is the LI-OmpA recombinant antigen peptide, which is packaged and stored at -70°C or below for future use.

[0016] As an optional or preferred embodiment, in the above kit, the coating method of the LI-OmpA recombinant antigen peptide is as follows: dilute the LI-OmpA recombinant antigen peptide to 1 μg / mL with a coating solution of pH 9.6, add it to a coating plate, 100 μL / well, incubate at 4°C overnight, wash three times with PBST, add a blocking solution and block overnight, discard the blocking solution the next day, dry naturally at room temperature with a humidity of 40%, and seal the coating plate with a film sealing machine to complete the coating.

[0017] As an optional or preferred solution, in the above kit, the horseradish peroxidase-labeled LI-OmpA recombinant antigen peptide monoclonal antibody 5F2 is prepared by the following method:

[0018] 1) Balb / C mice were immunized with the prepared LIOmpA recombinant antigen peptide by multiple subcutaneous injections. Blood was collected 7 days after 3 immunizations to detect serum antibody titers. The indirect ELISA method established in this laboratory was used to detect the mouse serum antibody titers. The mice with the highest antibody titers were selected for shock immunization. Three days after shock immunization, cell fusion of myeloma cells SP2 / 0 and spleen cells of immunized mice was performed.

[0019] 2) 10 to 14 days after cell fusion, when the cell clones to be fused grow to cover 1 / 2 of the bottom of the well, the positive clone wells are screened by indirect ELISA and four rounds of subcloning are performed by limiting dilution to establish the positive hybridoma cell line 5F2.

[0020] 3) Monoclonal antibody 5F2 was labeled by periodate oxidation method, and the concentration of enzyme-labeled antibody harvested after dialysis was adjusted to

[0021] 4±0.05mg / ml, add an equal volume of glycerol as the stock solution. Aliquot, 1ml / tube, and store at -70℃ or below for a long time.

[0022] 4) Protective agent The enzyme-labeled antibody stock solution was diluted 5000 times and sterilized by filtration with a 0.22 μm filter membrane to obtain the enzyme-labeled antibody in the above kit.

[0023] As an optional or preferred solution, any of the above kits further comprises:

[0024] Positive control serum: porcine ileitis live vaccine For immunization of SPF pigs, the protective agent was diluted at a volume ratio of 1:32;

[0025] Negative control serum: serum obtained from SPF pig blood, diluted with protective agent at a volume ratio of 1:32;

[0026] Sample diluent: 8.00g sodium chloride (NaCl), 2.90g disodium hydrogen phosphate dodecahydrate, 0.20g potassium dihydrogen phosphate, 0.20g potassium chloride, 0.20g sodium thimerosal, add water for injection to 1000ml to obtain a clear solution;

[0027] Preparation of 20-fold concentrated washing solution: Tween 20 10.00ml, sodium chloride 160.00g, disodium hydrogen phosphate dodecahydrate 58.00g, potassium dihydrogen phosphate 4.00g, potassium chloride 4.00g, sodium thimerosal 4.00g, add water for injection to 1000ml, which is a clear solution;

[0028] Substrate color development solution: commercial reagent TMB color development solution.

[0029] Stop solution: Take 27.20 ml of concentrated sulfuric acid and add it to 900 ml of water for injection to make a clear solution. Add water for injection to 1000 ml.

[0030] illustrate:

[0031] pET-30a(+): An expression vector containing a kanamycin resistance gene. The corresponding expression host bacteria is Escherichia coli, which is used to express the target gene. The genome contains protein tags N-His, N-T7 or C-His, and expression can be induced by IPTG or lactose and its analogs.

[0032] Escherichia coli BL21: A widely used host bacteria for protein expression, also known as Escherichia coli BL21 (DE3). The chromosome carries the T7 RNA polymerase gene controlled by the lacUV5 promoter, and can efficiently express the exogenous target gene driven by the T7 promoter under IPTG induction.

[0033] IPTG: Isopropyl-β-D-thiogalactoside, with the chemical formula C9H18O5S, can cause the transcription process of the lactose operon, thereby inducing the expression of the corresponding proteins of the downstream genes of the lactose operon.

[0034] Coating solution: 1.59 g sodium carbonate, 2.93 g sodium bicarbonate, add 900 mL water for injection, adjust the pH to 9.6, and make up to 1000 mL.

[0035] Blocking solution: bovine serum albumin (BSA) 5.00g, commercially available; sodium chloride 8.00g, commercially available; disodium hydrogen phosphate dodecahydrate 2.90g, commercially available; potassium dihydrogen phosphate 0.20g, commercially available; potassium chloride 0.20g, commercially available; Tween 20 0.5ml, commercially available; sodium thimerosal 0.20g, commercially available; add water for injection to 1000ml and store at 2-8°C for later use.

[0036] Protective agent bovine serum albumin (BSA) 5.00g, commercially available; Tween 20 (Tween-20) 0.50ml, commercially available; sodium chloride (NaCl) 8.00g, commercially available disodium hydrogen phosphate dodecahydrate (Na2HPO4·12H2O) 2.90g, commercially available potassium dihydrogen phosphate (KHPO4) 0.20g, commercially available potassium chloride 0.20g, commercially available; sucrose 2.00g, commercially available sodium thimerosal 0.20g, commercially available; add water for injection to 1000ml and store at 2-8°C for later use.

[0037] Compared with the prior art, the present invention has the following beneficial effects:

[0038] The blocking ELISA kit for detecting antibodies to intracellular Lawsoniae provided by the present invention uses the LI-OmpA recombinant antigen peptide with good conservatism, thermal stability and immunogenicity as the coating antigen, and uses the specific monoclonal antibody 5F2 against the LI-OmpA recombinant antigen peptide as the enzyme-labeled secondary antibody, and can detect whether there is LI infection by detecting antibodies in serum. Compared with pathogen detection, the antibodies in serum last longer, which can effectively improve the accuracy of detection. And the specificity, sensitivity and repeatability of this kit are all good.

[0039] Description of the deposit and survival information of the microorganisms of the present invention

[0040] Biological deposit name: Hybridoma cell line 5F2

[0041] Latin name: Hybridoma cell line 5F2

[0042] Deposit number: CCTCCNO: C2023263

[0043] Collection Unit: China Center for Type Culture Collection

[0044] Deposit address: Wuhan University, Wuhan, China, 430072

[0045] Deposit date: September 15, 2023 BRIEF DESCRIPTION OF THE DRAWINGS

[0046] Figure 1 : Construction diagram of pET30a-ompA plasmid of the present invention;

[0047] Figure 2 : Identification diagram of the target fragment of ompA amplified by PCR of the present invention;

[0048] Figure 3 : Double enzyme digestion identification diagram of pET30a-ompA plasmid of the present invention;

[0049] Figure 4: Schematic diagram of the SDS-PAGE Coomassie Brilliant Blue staining identification results of the 5F2 ascites monoclonal antibody purification in the present invention;

[0050] Figure 5 : The bar graph of serum antibody levels after challenge with Lawsonia intracellularis detected by blocking ELISA in the present invention.

[0051] Description of the sequence listing:

[0052] (1) Sequence Listing SEQ ID NO: 2 is the amino acid sequence listing of ompA in the pET30a-ompA recombinant plasmid in Example 1 of the present invention. The specific amino acid sequence is as follows:

[0053]

[0054] (2) Sequence Listing SEQ ID NO: 1 is a nucleotide sequence listing of ompA in the pET30a-ompA recombinant plasmid in Example 1 of the present invention. The specific nucleotide sequence is as follows:

[0055]

[0056]

[0057] (3) Sequence Listing SEQ ID NO: 3 is the upstream primer ompA-F for amplifying the LI-ompA gene in Example 1 of the present invention, and the specific nucleotide sequence is as follows.

[0058] gtggatccgttacagctagttgtactaaac

[0059] (4) Sequence Listing SEQ ID NO: 4 is the downstream primer ompA-R for amplifying the LI-ompA gene in Example 1 of the present invention, and the specific nucleotide sequence is as follows.

[0060] Cggcggccgcctaatcaaaaaagacaagttct. DETAILED DESCRIPTION

[0061] The present invention will be further described below in conjunction with specific embodiments, and the advantages and features of the present invention will become clearer as the description proceeds. However, it should be understood that the embodiments are exemplary only and do not constitute any limitation to the scope of the present invention. It should be understood by those skilled in the art that the details and forms of the technical solution of the present invention may be modified or replaced without departing from the spirit and scope of the present invention, but these modifications or replacements all fall within the protection scope of the present invention.

[0062] Example 1 LIOmpA gene cloning, expression, and protein purification

[0063] 1.1 Strains and plasmids

[0064] The pET30a(+) plasmid is a commonly used plasmid preserved by our laboratory and is used to construct the LI-OmpA recombinant antigen peptide; the coding nucleotide sequence of the ompA gene is shown in the sequence table SEQ ID NO: 2.

[0065] 1.2 Main experimental reagents and consumables

[0066] SDS-PAGE kit was purchased from Yazyme; RBCA protein quantification kit and BeyoGold TM His-tag Purification Resin (reduction-resistant chelating type) and IPTG were purchased from Biyuntian Company; Tween-20 was purchased from Nanjing Yifeixue Biotechnology Company; LB solid powder was purchased from Oxoid Company; from Proteintech Company; cell culture plates were purchased from Biofil Company; other chemical reagents were commercially available reagents. They were prepared by the laboratories of the College of Animal Science and Technology and the College of Veterinary Medicine where the applicant is located, and the purity was analytically pure.

[0067] 1.3 Construction of LI-ompA prokaryotic expression plasmid

[0068] 1.3.1 Cloning of LI ompA gene

[0069] Based on the bioinformatics prediction results of LI ompA, ompA without signal peptide and transmembrane region was designed, and the recombinant plasmid map was constructed using snapGene3.2.1 (see Figure 1 ) and designed upstream and downstream primers: ompA-F, ompA-R, the primers contain restriction sites BamH-Ⅰ and Not-Ⅰ, and the primers were synthesized by Wuhan Qingke Biotechnology Co., Ltd. The sequence information is shown in the sequence table SEQ ID NO: 3-4. The PCR reaction system for amplifying the ompA gene is as described in Table 1:

[0070] Table 1 PCR reaction system for amplifying ompA gene

[0071]

[0072] According to the above reaction system, the target fragment was amplified by the reaction program of 98°C pre-denaturation for 3 min, 98°C denaturation for 15 s, 50°C annealing for 15 s, 72°C extension for 15 s, 30 cycles, and 72°C extension for 3 min. The amplified fragment size was 1023 bp (see Figure 2 ).

[0073] 1.3.2 Construction of recombinant plasmid pET30a-ompA

[0074] When the 1% agarose gel was positive, the ompA fragment was recovered by cutting the gel. The reaction sample was added with 5× Loading Buffer and mixed. After 1% agarose gel electrophoresis, the target band was cut and the target gene was recovered and purified according to the instructions of the DNA purification and recovery kit. Using pET30a as the vector, BamH-Ⅰ and Not-Ⅰ were digested and connected to pET30a(+) and the above PCR amplification product to construct the recombinant plasmid pET30a-ompA. The double enzyme digestion identification results showed that the recombinant plasmid was successfully constructed (see Figure 3 ).

[0075] 1.4 Expression and purification of LIOmpA recombinant antigen peptide

[0076] First, the E. coli containing the pET30a-ompA recombinant plasmid stored in the ultra-low temperature freezer was revived, and 100 μL of the bacteria was evenly spread on the Kana resistance plate and cultured at 37°C overnight. A single colony was picked and placed in 700 μL of LB liquid culture medium with Kana resistance and shaken at 37°C for about 8-12 hours. 100 μL of the above bacterial liquid was inoculated into 10 ml of LB liquid culture medium with Kana resistance and shaken at 37°C for about 8-12 hours to obtain the revived recombinant expression bacteria. The revived strain was inoculated into 1L of LB liquid culture medium with Kana resistance and shaken at 37°C until the OD 450nm The value was changed to 0.6-0.8. The OmpA recombinant protein was expressed by induction with IPTG at a final concentration of 0.8 mmol / L at 25°C for 16 h. The purified LI-ompA recombinant antigen was obtained by His tag affinity chromatography. After the recombinant protein was dialyzed and concentrated, the protein concentration was determined by the BCA method (conventional method) and stored in 1.5 ml Eppendorf tubes at -80°C for later use.

[0077] Example 2 Preparation and enzyme labeling of LIOmpA recombinant antigen peptide monoclonal antibody 5F2

[0078] 2.1 Cell lines and experimental animals

[0079] Myeloma cells SP2 / 0 were stored in the laboratories of the College of Animal Science and Technology and the College of Veterinary Medicine of the applicant; 6-8 week old female Balb / c mice were purchased from Henan Sikebes Biotechnology Co., Ltd.

[0080] 2.2 Main reagents and test consumables

[0081] PMI Medium 1640 basic (1x) was purchased from Gibco; Freund's complete adjuvant (FCA), Freund's incomplete adjuvant (FIA), and DMSO were purchased from Sigma; FBS serum was purchased from Yeasen; HRP-labeled goat anti-mouse IgG antibody; horseradish peroxidase (HRP); other chemical reagents were commercially available reagents. The reagents were prepared by the laboratory of the College of Animal Science and Technology and the College of Veterinary Medicine where the applicant is located, and the purity was analytically pure.

[0082] 2.3 Test methods

[0083] 2.3.1 Mouse immunization: The immunization antigen was the prepared LIOmpA recombinant antigen peptide. The immunization procedure was as follows: 200 μg of LIOmpA recombinant antigen peptide was emulsified with Freund's complete adjuvant at a volume ratio of 1:1, and then Balb / C mice were immunized by subcutaneous multiple injections. On days 14 and 28, the same dose of recombinant protein was emulsified with Freund's incomplete adjuvant at a ratio of 1:1 for the second and third immunizations. Blood was collected 7 days after the third immunization to detect serum antibody titers. After the conventional indirect ELISA method was used to detect mouse serum antibody titers of 1:12800, mice with the highest antibody titer were selected for shock immunization. Three days after shock immunization, cell fusion of myeloma cells SP2 / 0 and spleen cells of immunized mice was performed, and hybridoma cells were screened using HAT complete medium.

[0084] 2.3.2 Establishment of positive hybridoma cell line: 10 to 14 days after cell fusion, when the cell clones to be fused grow to cover 1 / 2 of the bottom of the well, the positive clone wells are screened by indirect ELISA and four rounds of subcloning are performed by limiting dilution to establish the positive hybridoma cell line 5F2. During the subcloning period, the culture medium is replaced with HT complete medium.

[0085] 2.3.3 Identification of monoclonal antibodies: Monoclonal positive hybridoma cells were cultured, and hybridoma cell chromosome counts, monoclonal antibody subclass identification, and monoclonal antibody reactivity with antigens were analyzed. The number of chromosomes of the 5F2 hybridoma cell line was 100 to 110, and the antibody subclass was IgG2a / κ. WB verification showed that 5F2 could bind to intracellular Lawsonia spp. and had good reactivity. Protein electrophoresis identified that the purified antibody had clear bands and a purity of >85%, indicating that the antibody purity was high (see Figure 4 ). The LIOmpA recombinant antigen peptide monoclonal antibody 5F2 was determined as the raw material for the detection method in this application.

[0086] 2.3.4 Labeling of monoclonal antibody 5F2: Weigh 5 mg horseradish peroxidase (HRP) and dissolve it in 1 ml double distilled water, add 500 μl freshly prepared NaIO4, react at 2-8°C for 30 min, the solution turns grass green, then add 0.5 ml ethylene glycol, mix well and react at room temperature in the dark for 30 min. Then add 5 mg purified 5F2 monoclonal antibody and dialyze in carbonate buffer with pH 9.5 at 2-8°C for 15 h. The next day, add 0.2 ml freshly prepared NaBH4 to the solution, mix well and react at 2-8°C for 2 h, then add an equal volume of saturated ammonium sulfate solution, let stand at 2-8°C for 30 min, centrifuge at 7000 r / min for 10 min, discard the supernatant, resuspend in PB, and dialyze in PB at 2-8°C for 1.5 h. Collect the contents of the dialysis bag, adjust the concentration of the enzyme-labeled antibody to 4 mg / ml, add an equal volume of glycerol as the enzyme-labeled antibody stock solution, dispense into 1 ml / tube, and store at -70°C or below for future use.

[0087] Example 3 Preparation, Assembly and Use of Blocking ELISA Kit for Lawsonia intracellularis Antibodies

[0088] 3.1 Preparation and assembly of kit components

[0089] 3.1.1 Preparation of antigen-coated plates: dilute the coating antigen with coating solution to a final concentration of 1 μg / ml, add 100 μl to each well of a 96-well ELISA plate, and incubate at 2-8°C for 15 hours; discard the coating solution, add 200 μl of blocking solution to each well, and incubate at 37°C for 2 hours; pat dry, and dry at 37°C for 2 hours. Seal the antigen-coated plate with packaging film and store at 2-8°C for later use.

[0090] 3.1.2 Preparation of enzyme-labeled antibodies: Dilute the enzyme-labeled antibody stock solution 5000 times with a protective agent and filter it with a 0.22μm filter membrane for sterilization to obtain the enzyme-labeled antibody.

[0091] 3.1.3 Preparation of positive control: Select healthy SPF pigs aged 7 to 8 weeks, and test LI negative by PCR. The instructions dilute the vaccine, and immunize 10 heads per head by gavage, with a booster immunization every 14 days, and blood collection 14 days after the second immunization. Blood is collected from the vein aseptically, and after the blood is fully coagulated, it is centrifuged at 4000r / min for 10 minutes, the serum is separated, inactivated at 60℃ for 30 minutes, sodium thimerosal is added with a final concentration of 0.01%, and stored at -70℃ or below for use. Dilute 60 times with a protective agent, and test positive with a commercial indirect ELISA test kit, and filter with a 0.22μm filter, which is the positive control.

[0092] 3.1.4 Preparation of negative control: Use healthy SPF pigs aged 7 to 8 weeks to collect blood from the vein aseptically. After the blood is fully coagulated, centrifuge at 4000r / min for 10 minutes to separate the serum, inactivate at 60℃ for 30 minutes, add sodium thimerosal with a final concentration of 0.01%, and store at -70℃ or below for use. Dilute 60 times with protective agent and test negative with a commercial indirect ELISA detection kit, filter with a 0.22μm filter, which is the negative control.

[0093] 3.1.5 Preparation of sample diluent: Sodium chloride (NaCl) 8.00 g, disodium hydrogen phosphate dodecahydrate (Na2HPO4·12H20) 2.90 g, potassium dihydrogen phosphate (KH2PO4) 0.20 g, potassium chloride (KC1) 0.20 g, sodium thimerosal 0.20 g (all the above reagents are commercially available) add water for injection to 1000 ml to obtain a clear solution.

[0094] 3.1.6 Preparation of 20-fold concentrated washing solution: 10.00 ml of Tween-20, 160.00 g of sodium chloride (NaCl), 58.00 g of disodium hydrogen phosphate dodecahydrate (Na2HPO4·12H2O), 4.00 g of potassium dihydrogen phosphate (KH2PO4), 4.00 g of potassium chloride (KCl), 4.00 g of sodium thimerosal (all the above reagents are commercially available); add water for injection to 1000 ml to obtain a clear solution.

[0095] 3.1.7 Preparation of substrate colorimetric solution: The substrate colorimetric solution used in this kit is the commercial reagent TMB colorimetric solution, which is a clear solution.

[0096] 3.1.8 Preparation of stop solution: Take 27.20 ml of concentrated sulfuric acid and add it to 900 ml of water for injection to make a clear solution. Add water for injection to 1000 ml.

[0097] 3.1.9 Assembly of the kit: The components of the kit are assembled as shown in the table below.

[0098] (1) 2 or 5 antigen-coated plates (96 wells / plate)

[0099] (2) 1 bottle of enzyme-labeled antibody (10 ml / bottle or 25 ml / bottle);

[0100] (3) 1 tube of positive control (1 ml / tube or 2 ml / tube);

[0101] (4) 1 tube of negative control (1 ml / tube or 2 ml / tube);

[0102] (5) One bottle of sample diluent (50 mL or 100 mL);

[0103] (6) 1 bottle of 20 times concentrated detergent (30 ml / bottle or 75 ml / bottle);

[0104] (7) 1 bottle of substrate color development solution (20 ml / bottle or 50 ml / bottle);

[0105] (8) 1 bottle of stop solution (10 ml / bottle or 25 ml / bottle).

[0106] 3.2 Usage and determination of the kit

[0107] 3.2.1 Usage of the kit

[0108] (1) Sample preparation: Take whole blood from the animal, wait for the blood to coagulate, centrifuge at 4000r / min for 10 minutes, and collect the serum; or wait for the blood to coagulate and precipitate naturally, and then collect the serum. The serum should be clear and free of hemolysis.

[0109] (2) Preparation of washing solution: Before use, dilute the 20-fold concentrated washing solution with distilled water or pure water (for example, 10 ml of concentrated washing solution plus 190 ml of pure water), mix well, and store at 2-8°C for 7 days.

[0110] (3) Dilution of test serum and controls: dilute the test serum in a serum dilution plate at a ratio of 1:1 (e.g., add 100 μl of test serum to 100 μl of sample diluent). Negative and positive controls are not diluted.

[0111] (4)(4) Take the antigen-coated plate (it can be disassembled and used in batches depending on the number of samples): first wash the antigen-coated plate once with 1× washing solution, add 100μl of the diluted serum to be tested, negative control and positive control to the antigen-coated plate, set up 1 well for each serum to be tested, and 2 wells for each negative and positive control, gently shake the samples in the wells to mix well, and incubate at 37°C for 1 hour.

[0112] (5)(4) Discard the liquid in the wells and add 200 μl of 1× washing solution to each well. Repeat the washing process 5 times and pat dry for the last time.

[0113] (6)(5) Add 100 μl of the enzyme marker to each well and incubate at 37°C for 30 minutes. (6) Discard the liquid in the wells, wash 5 times, and pat dry for the last time.

[0114] (7) Add 100 μl of substrate color development solution to each well and incubate at 20-25°C in the dark for 15 minutes.

[0115] (8) Add 50 μl of stop solution to each well and measure the results within 10 minutes (lightly shake on an oscillator before measurement).

[0116] 3.2.2 Determination: Measure the OD450nm value of each well on the microplate reader. The test is established if the average OD450nm value of the negative control is greater than 1.0 and the inhibition rate of the positive control is greater than 50%.

[0117] S = sample well OD 450nm Value, N = negative control OD 450nm value.

[0118] PI value = (1-S / N) x 100%.

[0119] If the inhibition rate of the sample under test is less than 30%, the sample is judged to be negative for the intracellular Lawsonia antibody. If the inhibition rate of the sample under test is ≥ 30%, the sample is judged to be positive for the intracellular Lawsonia antibody.

[0120] (Note: If the sample OD 450nm Value>negative control OD 450nm value, the inhibition rate is regarded as 0.00%. )

[0121] Example 4 Performance Analysis of Lawsonia intracellularis Antibody Blocking ELISA Kit

[0122] 4.1 Sensitivity test

[0123] One box of each of the three batches of blocking ELISA kits was randomly selected and tested with positive sensitivity control serum of Lawsonia intracellularis from 2 0 Dilute to 2 4 According to the use and precautions of the kit, the OD450nm value of each serum dilution was detected and the blocking rate was calculated. The results showed that at a serum dilution of 2 3 The blocking rates were 48.13%, 41.62%, and 46.43%, respectively, and they were still judged as positive (see Table 2). Therefore, this method can detect up to 8-fold dilution.

[0124] Table 2 Sensitivity test of blocking ELISA

[0125]

[0126] 4.2 Specificity test

[0127] The laboratory-preserved swine fever virus (CSFV), porcine blue ear virus (PRRSV), porcine epidemic diarrhea virus (PEDV), foot-and-mouth disease virus (FMDV), pseudorabies virus (PRV), porcine circovirus type Ⅰ (PCV-Ⅰ), Pasteurella multocida (PM), positive serum, Actinobacillus pleuropneumoniae (APx), Escherichia coli (E.coil), and type Ⅱ Streptococcus suis (SS-2) pig positive serum were taken, and the OD450nm value of the corresponding blood was detected with the trial-made blocking ELISA kit and the blocking rate was calculated. The blocking ELISA test results showed that except for the positive serum of intracellular Lawsonia intracellularis antibody, the blocking rates of the other positive serums of pathogen antibodies were all <30% (see Table 3).

[0128] Table 3 Specificity test of blocking ELISA

[0129]

[0130]

[0131] 4.3 Repeatability test

[0132] 4.3.1 Repeated testing within a batch

[0133] Three kits were randomly selected from the same batch of test kits, and a total of 8 clinically negative, weakly positive and strongly positive sera were tested to calculate the blocking rate. The coefficient of variation CV was calculated based on the PI value, which showed whether the intra-batch repeatability was good. The blocking rate coefficient of variation of three repetitions of different sera within the batch was less than 10%, indicating that the intra-batch coefficient of variation was good (see Table 4).

[0134] Table 4 Intra-batch repeat tests

[0135]

[0136] 4.3.2 Repeated testing between batches

[0137] One kit was randomly selected from each of the three batches of trial kits, and a total of 8 sera, including negative, weakly positive and strongly positive sera, were tested clinically to calculate the blocking rate. The coefficient of variation CV was calculated based on the PI value, from which it can be seen whether the batch reproducibility of this method is good. The blocking rate coefficient of variation of three repetitions of different sera between batches was less than 15%, indicating that the batch variation coefficient was good (see Table 5).

[0138] Table 5 Batch repeat test

[0139]

[0140] 4.4 Comparison between blocking ELISA and commercial ELISA

[0141] 150 clinical sera were tested simultaneously using a commercial indirect ELISA test kit and the trial-produced intracellular Lawsonia antibody blocking ELISA kit of the present invention. The use and result determination of the trial-produced intracellular Lawsonia antibody blocking ELISA kit of the present invention were performed with reference to the use and precautions of the kit in Example 3.2 of this embodiment, and compared with the commercial indirect ELISA test results, the compliance rate was calculated (see Table 6).

[0142] Table 6 Conformity of samples detected by blocking ELISA and commercial ELISA

[0143]

[0144] Example 5 Application of Lawsonia intracellularis antibody blocking ELISA kit in the evaluation of immune antibody levels

[0145] Ten SPF pigs were randomly divided into two groups, 5 in each group, and fed normally for 3 days to adapt to the environment. For the intestinal tissues tested positive clinically, the mucosa, ileum and colon were scraped and mixed in a ratio of 1:1, and the diluent was added and mixed thoroughly. The mixture was stored at 4°C for later use. On the 4th day, the above solution was administered orally with a bacterial count of 10 7 100 copies / ml, 30 ml per head, once in the morning and once in the evening, twice in total. At the same time, the control group pigs were gavaged with an equal amount of normal saline. Blood was collected from all test pigs before the challenge (counted as 0d) and 7d, 14d, 21d, and 28d after the challenge, and the serum was separated to detect the antibody level. The results showed that all pigs were serum antibody positive at 21d and 28d after the challenge, while the antibodies of the non-challenged control group were all negative, indicating that the intracellular Lawsonia antibody blocking ELISA kit can be used as an evaluation of the antibody efficacy of intracellular Lawsonia after the challenge (see Figure 5 ).

[0146] The above description is only a specific implementation of the present invention, but the protection scope of the present invention is not limited thereto. Any person familiar with the technology can understand and think of any changes or substitutions within the technical scope disclosed by the present invention, which should be included in the scope of the present invention. Therefore, the protection scope of the present invention should be based on the protection scope of the claims.

Claims

1. A blocking ELISA kit for detecting antibodies to Lawsonia intracellularis, characterized in that: The kit comprises an ELISA plate coated with a LI-OmpA recombinant antigen peptide, and the amino acid sequence of the LI-OmpA recombinant antigen peptide is shown in SEQ ID NO:

1.

2. The kit according to claim 1, characterized in that The nucleotide sequence of the gene encoding the LI-OmpA recombinant antigen peptide is shown in SEQ ID NO:

2.

3. The kit according to claim 1, characterized in that The coating concentration of the LI-OmpA recombinant antigen peptide is 1 μg / mL.

4. The kit according to claim 1, characterized in that The kit also includes enzyme-labeled antibodies.

5. The kit according to claim 4, wherein the enzyme marker is a LI-OmpA recombinant antigen peptide monoclonal antibody produced by hybridoma cell line 5F2, which is deposited in China Center for Type Culture Collection with a deposit number of CCTCCNO: C2023263.

6. The kit according to claim 4, characterized in that The dilution volume ratio of the enzyme-labeled antibody was 1:5000.

7. The kit according to claim 1, characterized in that The detection kit also includes a positive control, a negative control, a sample diluent, a 20-fold concentrated washing solution, a substrate color developing solution and a stop solution.

8. A blocking ELISA method for detecting antibodies to Lawsonia intracellularis, characterized in that: The detection method is obtained based on the blocking ELISA kit for detecting antibodies against Lawsonia intracellularis according to any one of claims 1 to 8.

9. The blocking ELISA method for detecting antibodies to Lawsonia intracellularis according to claim 9, characterized in that: The method comprises the following steps: Coating: Dilute the purified LIOmpA protein to 1 μg / mL with 0.05 mol / L carbonate buffer (pH 9.6) and coat the ELISA plate. Add 100 μL to each well and incubate overnight at 4°C. Washing: shake off the liquid in the plate, add 300 μL PBST to each well, wash 5 times, and pat dry; Blocking: Use 200 μL of the blocking solution per well and block at 37°C for 2 h; Washing: shake off the liquid in the plate, add 300 μL PBST to each well, wash 5 times, and pat dry; Drying and sealing: Dry at 37°C for 2 hours, seal the antigen-coated plate with packaging film, and store it at 2-8°C for later use. Sample preparation: Dilution of test serum and controls The test serum was diluted 1:1 by volume in a serum dilution plate. Negative and positive controls were not diluted. Sample addition: Depending on the amount of samples, it can be disassembled for use or used in batches. The steps are as follows: take the antigen-coated plate and first use 1× washing solution, which is diluted from 20-fold concentrated washing solution; wash the antigen-coated plate once, take 100μ1 of the diluted serum to be tested, negative control and positive control respectively and add them to the antigen-coated plate, set 1 well for each serum to be tested, and 2 wells for each negative and positive control, gently shake the samples in the wells and incubate at 37°C for 1 hour; Washing: discard the liquid in the wells, add 200 μl of 1× washing solution to each well, repeat washing 5 times, and pat dry for the last time; Antibody incubation: Add 100 μl of enzyme-labeled reagent to each well and incubate at 37°C for 30 minutes; Washing: discard the liquid in the wells, wash 5 times, and pat dry for the last time; Color development: Add 100 μl of substrate color development solution to each well and place at 20-25°C in the dark for 15 minutes; Stop: Add 50 μl of stop solution to each well and measure the results within 10 minutes (shake gently on an oscillator before measurement); Reading: Measure the OD450nm value of each well on an ELISA reader.

10. The blocking ELISA method for Lawsonia intracellularis antibodies according to claim 9, characterized in that: The conditions for the test to be established are that the average OD450nm value of the negative control is greater than 1.0, and the inhibition rate of the positive control is greater than 50%; if the inhibition rate of the tested sample is less than 30%, the sample is judged to be negative for the intracellular Lawsonia antibody; if the inhibition rate of the tested sample is ≧30, the sample is judged to be positive for the intracellular Lawsonia antibody.

Citation Information

Patent Citations

  • ELISA (Enzyme Linked Immunosorbent Assay) kit for detecting lawsonia intracellularis antibody

    CN103698514A

  • Culture method and application of lawsonia intracellularis

    CN110468088A

  • Recombinant vaccine against proliferative enteropathy in animals

    CN111655282A

  • Fluorescent quantitative PCR (Polymerase Chain Reaction) primer probe group for detecting swine bacterial diarrhea pathogens

    CN117144029A

  • ELISA (enzyme-linked immunosorbent assay) detection kit and method for lawsonia intracellularis antibody

    CN118112239A

Cited By

  • Porcine Lawsonia intracellularis antibody detection test paper and application thereof

    CN120559226A